Publication list

Publication list

Lourdudoss C, Di Giuseppe D, Wolk A,  Westerlind H,  Klareskog L,  Alfredsson L,  van Vollenhoven RF,  Lampa J. Dietary Intake of Polyunsaturated Fatty Acids and Pain in Spite of Inflammatory Control Among Methotrexate-Treated Early Rheumatoid Arthritis Patients. Arthritis care & research 2018 70;2 205-212

Manouchehrinia A, Westerlind H, Kingwell E,  Zhu F,  Carruthers R,  Ramanujam R,  Ban M,  Glaser A,  Sawcer S,  Tremlett H,  Hillert J. Age Related Multiple Sclerosis Severity Score: Disability ranked by age. Multiple sclerosis (Houndmills, Basingstoke, England) 2017 23;14 1938-1946

Manivel VA, Mullazehi M, Padyukov L,  Westerlind H,  Klareskog L,  Alfredsson L,  Saevarsdottir S,  Rönnelid J. Anticollagen type II antibodies are associated with an acute onset rheumatoid arthritis phenotype and prognosticate lower degree of inflammation during 5 years follow-up. Annals of the rheumatic diseases 2017 76;9 1529-1536

Westerlind H, Mellander MR, Bresso F,  Munch A,  Bonfiglio F,  Assadi G,  Rafter J,  Hübenthal M,  Lieb W,  Källberg H,  Brynedal B,  Padyukov L,  Halfvarson J,  Törkvist L,  Bjork J,  Andreasson A,  Agreus L,  Almer S,  Miehlke S,  Madisch A,  Ohlsson B,  Löfberg R,  Hultcrantz R,  Franke A,  D’Amato M. Dense genotyping of immune-related loci identifies HLA variants associated with increased risk of collagenous colitis. Gut 2017 66;3 421-428

Westerlind H, Stawiarz L, Fink K,  Hillert J,  Manouchehrinia A. Re: Declines in the diagnosis of primary progressive MS-A critical change in phenotype or critical measurement error?. Multiple sclerosis (Houndmills, Basingstoke, England) 2017 23;2 305-307

Song J, Karrenbauer V, Manouchehrinia A,  Almqvist C,  Hillert J,  Westerlind H. Similar familial risk in multiple sclerosis subgroups. Multiple sclerosis (Houndmills, Basingstoke, England) 2017 23;13 1782-1785

Westerlind H, Stawiarz L, Fink K,  Hillert J,  Manouchehrinia A. A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study. Multiple sclerosis (Houndmills, Basingstoke, England) 2016 22;8 1071-9

Westerlind H, Bonfiglio F, Mellander MR,  Hübenthal M,  Brynedal B,  Björk J,  Törkvist L,  Padyukov L,  Ohlsson B,  Löfberg R,  Hultcrantz R,  Franke A,  Bresso F,  D’Amato M. HLA Associations Distinguish Collagenous From Lymphocytic Colitis. The American journal of gastroenterology 2016 111;8 1211-3

Folkersen L, Brynedal B, Diaz-Gallo LM,  Ramsköld D,  Shchetynsky K,  Westerlind H,  Sundström Y,  Schepis D,  Hensvold A,  Vivar N,  Eloranta ML,  Rönnblom L,  Brunak S,  Malmström V,  Catrina A,  Moerch UG,  Klareskog L,  Padyukov L,  Berg L. Integration of known DNA, RNA and protein biomarkers provides prediction of anti-TNF response in rheumatoid arthritis: results from the COMBINE study. Molecular medicine (Cambridge, Mass.) 2016 22;

Westerlind H, Imrell K, Ramanujam R,  Myhr KM,  Celius EG,  Harbo HF,  Oturai AB,  Hamsten A,  Alfredsson L,  Olsson T,  Kockum I,  Koski T,  Hillert J. Identity-by-descent mapping in a Scandinavian multiple sclerosis cohort. European journal of human genetics : EJHG 2015 23;5 688-92

Westerlind H, Ramanujam R, Uvehag D,  Kuja-Halkola R,  Boman M,  Bottai M,  Lichtenstein P,  Hillert J. Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden. Brain : a journal of neurology 2014 137;Pt 3 770-8

Westerlind H, Boström I, Stawiarz L,  Landtblom AM,  Almqvist C,  Hillert J. New data identify an increasing sex ratio of multiple sclerosis in Sweden. Multiple sclerosis (Houndmills, Basingstoke, England) 2014 20;12 1578-83

Westerlind H, Kuja-Halkola R, Ramanujam R,  Hillert J. Reply: Shared environmental effects on multiple sclerosis susceptibility: conflicting evidence from twin studies. Brain : a journal of neurology 2014 137;Pt 7 e288-

Int IBD Genetics Consortium IIBDGC, Wellcome Trust Case Control Consor, Beecham AH,  Patsopoulos NA,  Xifara DK,  Davis MF,  Kemppinen A,  Cotsapas C,  Shah TS,  Spencer C,  Booth D,  Goris A,  Oturai A,  Saarela J,  Fontaine B,  Hemmer B,  Martin C,  Zipp F,  D’Alfonso S,  Martinelli-Boneschi F,  Taylor B,  Harbo HF,  Kockum I,  Hillert J,  Olsson T,  Ban M,  Oksenberg JR,  Hintzen R,  Barcellos LF,  Agliardi C,  Alfredsson L,  Alizadeh M,  Anderson C,  Andrews R,  Sondergaard HB,  Baker A,  Band G,  Baranzini SE,  Barizzone N,  Barrett J,  Bellenguez C,  Bergamaschi L,  Bernardinelli L,  Berthele A,  Biberacher V,  Binder TMC,  Blackburn H,  Bomfim IL,  Brambilla P,  Broadley S,  Brochet B,  Brundin L,  Buck D,  Butzkueven H,  Caillier SJ,  Camu W,  Carpentier W,  Cavalla P,  Celius EG,  Coman I,  Comi G,  Corrado L,  Cosemans L,  Cournu-Rebeix I,  Cree BAC,  Cusi D,  Damotte V,  Defer G,  Delgado SR,  Deloukas P,  di Sapio A,  Dilthey AT,  Donnelly P,  Dubois B,  Duddy M,  Edkins S,  Elovaara I,  Esposito F,  Evangelou N,  Fiddes B,  Field J,  Franke A,  Freeman C,  Frohlich IY,  Galimberti D,  Gieger C,  Gourraud PA,  Graetz C,  Graham A,  Grummel V,  Guaschino C,  Hadjixenofontos A,  Hakonarson H,  Halfpenny C,  Hall G,  Hall P,  Hamsten A,  Harley J,  Harrower T,  Hawkins C,  Hellenthal G,  Hillier C,  Hobart J,  Hoshi M,  Hunt SE,  Jagodic M,  Jelcic I,  Jochim A,  Kendall B,  Kermode A,  Kilpatrick T,  Koivisto K,  Konidari I,  Korn T,  Kronsbein H,  Langford C,  Larsson M,  Lathrop M,  Lebrun-Frenay C,  Lechner-Scott J,  Lee MH,  Leone MA,  Leppa V,  Liberatore G,  Lie BA,  Lill CM,  Linden M,  Link J,  Luessi F,  Lycke J,  Macciardi F,  Mannisto S,  Manrique CP,  Martin R,  Martinelli V,  Mason D,  Mazibrada G,  McCabe C,  Mero IL,  Mescheriakova J,  Moutsianas L,  Myhr KM,  Nagels G,  Nicholas R,  Nilsson P,  Piehl F,  Pirinen M,  Price SE,  Quach H,  Reunanen M,  Robberecht W,  Robertson NP,  Rodegher M,  Rog D,  Salvetti M,  Schnetz-Boutaud NC,  Sellebjerg F,  Selter RC,  Schaefer C,  Shaunak S,  Shen L,  Shields S,  Siffrin V,  Slee M,  Sorensen PS,  Sorosina M,  Sospedra M,  Spurkland A,  Strange A,  Sundqvist E,  Thijs V,  Thorpe J,  Ticca A,  Tienari P,  van Duijn C,  Visser EM,  Vucic S,  Westerlind H,  Wiley JS,  Wilkins A,  Wilson JF,  Winkelmann J,  Zajicek J,  Zindler E,  Haines JL,  Pericak-Vance MA,  Ivinson AJ,  Stewart G,  Hafler D,  Hauser SL,  Compston A,  McVean G,  De Jager P,  Sawcer SJ,  McCauley JL. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. NATURE GENETICS 2013 45;11 1353-60

Link J, Kockum I, Lorentzen AR,  Lie BA,  Celius EG,  Westerlind H,  Schaffer M,  Alfredsson L,  Olsson T,  Brynedal B,  Harbo HF,  Hillert J. Importance of human leukocyte antigen (HLA) class I and II alleles on the risk of multiple sclerosis. PloS one 2012 7;5 e36779-

Jungedal R, Lundkvist M, Engdahl E,  Ramanujam R,  Westerlind H,  Sominanda A,  Hillert J,  Fogdell-Hahn A. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice. Multiple sclerosis (Houndmills, Basingstoke, England) 2012 18;12 1775-81

Fink K, Westerlind H, Lundkvist M,  Fogdell-Hahn A,  Hillert J. Clinical Outcomes in Patients with Multiple Sclerosis who Develop Neutralizing Antibodies to Recombinant Interferon-Beta Treatment. SCANDINAVIAN JOURNAL OF IMMUNOLOGY 2011 73;4 369-370

Fink K, Westerlind H, Lundkvist M,  Fogdell-Hahn A,  Hillert J. How do patients with neutralising antibodies to recombinant interferon-beta treatment develop in their clinical outcome?. JOURNAL OF NEUROLOGY 2011 258; 264-264

Lundstrom W, Greiner E, Lundmark F,  Westerlind H,  Smestad C,  Lorentzen AR,  Kockum I,  Link J,  Brynedal B,  Celius EG,  Harbo HF,  Masterman T,  Hillert J. No influence on disease progression of non-HLA susceptibility genes in MS. JOURNAL OF NEUROIMMUNOLOGY 2011 237;1-2 98-100